Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with stage I, stage II, or stage III esophageal cancer that can be removed by surgery.

Timeline

Start

2004-04

Primary completion

2006-11

Completion

2006-11

Outcome

Outcome not reported

Stopped (Enrollment): “Withdrawn for lack of funding and accrual”

Drugs

Indications